Session 3: Boosting primary and recurrent rectal cancer: how far can we push the radiotherapy envelope?

Abstract: Neoadjuvant pelvic radiotherapy is widely used for patients with advanced rectal cancer. The trade‐off between dose and response is well‐established, yet little consensus remains on the precise methods of delivery and doses given in different scenarios. Professor Vuong reviews the evidence base and trial evidence on the escalation of radiotherapy dose and the methods of achieving this. [ABSTRACT FROM AUTHOR]